Core Insights - Vorasidenib, the world's first dual-target IDH inhibitor, has been approved for clinical use in Beijing to treat patients with IDH-mutant diffuse gliomas, enhancing treatment options for this patient group [1][2] - The drug is designed to penetrate the blood-brain barrier and specifically targets IDH1 and IDH2 mutations, marking a significant breakthrough in the treatment of low-grade gliomas [2] - Vorasidenib's introduction in Beijing is facilitated by an innovative policy that accelerates the approval of urgently needed imported drugs, significantly reducing patient wait times for new therapies [3] Group 1 - Vorasidenib is now available in designated medical institutions in Beijing, with initial treatments taking place at major hospitals [1] - The drug addresses the high mortality and recurrence rates associated with IDH-mutant diffuse gliomas, where over 90% of patients experience recurrence despite current treatment options [1] - The median age of onset for patients with IDH-mutant diffuse gliomas is around 40 years, with many facing significant physical and psychological challenges post-surgery [1] Group 2 - Vorasidenib has received approvals in multiple countries, including the US, Canada, Australia, and others, with its introduction in Beijing being part of a broader strategy to enhance access to innovative treatments [3] - The 2024 NCCN guidelines and the Chinese Anti-Cancer Association's updated guidelines now recommend IDH inhibitors for postoperative adjuvant therapy in patients with IDH-mutant gliomas [2] - The inclusion of Vorasidenib in the Beijing Universal Health Insurance special drug list enhances patient access to this treatment, improving their overall treatment experience [3]